Skip to main content
Premium Trial:

Request an Annual Quote

Dicerna, Ipsen Ink RNAi Drug-Discovery Deal

Premium

Dicerna Pharmaceuticals said this week that it has signed a deal with French biotechnology firm Ipsen to develop RNAi-based therapeutics in the areas of oncology and endocrinology.

Under the terms of the deal, the companies will combine Dicerna's Dicer-substrate technology with Ipsen's peptide-based targeting vectors, which they said will allow cell-specific, intracellular delivery of the RNAi molecules.

Although the arrangement is focused on drug discovery, "Dicerna and Ipsen may collaborate further to move the programs discovered under this partnership into development and eventual commercialization," they noted.

Specific terms of the arrangement were not disclosed.